CreativeOne Wealth LLC Takes Position in GSK plc (NYSE:GSK)

CreativeOne Wealth LLC acquired a new stake in shares of GSK plc (NYSE:GSK) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 5,209 shares of the pharmaceutical company’s stock, valued at approximately $213,000.

Other institutional investors have also modified their holdings of the company. FMR LLC lifted its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC lifted its stake in GSK by 14.3% in the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares in the last quarter. Cerity Partners LLC lifted its stake in GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after acquiring an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC lifted its stake in GSK by 20.0% in the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after acquiring an additional 83,433 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Up 1.7 %

Shares of GSK stock opened at $34.90 on Wednesday. GSK plc has a 12-month low of $32.83 and a 12-month high of $45.92. The stock has a market cap of $72.32 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.31 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The business’s 50 day moving average is $37.03 and its 200-day moving average is $39.79.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be issued a dividend of $0.3928 per share. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.50%. GSK’s payout ratio is presently 99.35%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on GSK shares. Argus upgraded GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Seven analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.00% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.